Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


First vaccine for meningitis B

Written by | 14 Dec 2012 | All Medical News

by Gary Finnegan – EMA Highlights – The EMA has given the green light to a new vaccine for bacterial meningitis. Bexsero, by Novartis, provides broad coverage against the meningococcal group B infections and is intended for the immunisation of children aged two months and older.

The move was hailed by the public health community as it fills an unmet need in Europe where around 7,000 cases of invasive meningococcal disease are recorded each year.

Over 90% of cases of meningococcal meningitis and septicaemia are caused by five of the 13 meningococcal serogroups, specifically groups A, B, C, W135 and Y. In Europe, group B is the most prevalent meningococcal serogroup, with 3,406 to 4,819 cases reported annually between 2003 and 2007, according to a surveillance report published by the European Centre for Disease Control.

Vaccines have previously been authorised to protect against meningococcal disease caused by groups A, C, W135 and Y, but there had been no approved vaccine available that provides broad coverage against group B meningococcal disease.

The disease mainly affects infants and young children, but could occur also in older children and young adults. Despite the availability of medical treatment and effective antibiotics, 8% of European patients die and some 11-19% of survivors suffer life-long consequences, including permanent brain damage, learning disabilities and hearing loss.

There are currently some geographical regions within the EU with higher incidence rates, mainly in Belgium, Ireland, Spain and the United Kingdom.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.